NBIX - NEUROCRINE BIOSCIENCES INC
IEX Last Trade
139.47
0.665 0.477%
Share volume: 100
Last Updated: Fri 27 Dec 2024 03:30:14 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-1.15%
PREVIOUS CLOSE
CHG
CHG%
$138.80
0.66
0.48%
Fundamental analysis
51%
Profitability
68%
Dept financing
9%
Liquidity
51%
Performance
44%
Performance
5 Days
-0.34%
1 Month
6.74%
3 Months
17.77%
6 Months
0.52%
1 Year
4.07%
2 Year
14.80%
Key data
Stock price
$139.47
DAY RANGE
$138.80 - $138.80
52 WEEK RANGE
$112.20 - $157.98
52 WEEK CHANGE
$3.31
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Kevin C. Gorman
Region: US
Website: neurocrine.com
Employees: 1,200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: neurocrine.com
Employees: 1,200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. Company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease.
Recent news